Patients with SSc with diffuse cutaneous involvement (dcSSc) demonstrated a relatively higher positivity for anti-PRMT5 antibody compared with the patients with SSc with limited cutaneous involvement (lcSSc) but without statistical significance (dcSSc vs lcSSc: 56.34% vs 43.66%, p=0.179, figure 5C). Here, PRMT5 is linked to systemic sclerosis.